Charles River builds Chinese presence with WuXi acquisition
This article was originally published in Scrip
Executive Summary
The US-based drug research services firm Charles River Laboratories has entered into a definitive agreement to acquire WuXi PharmaTech in a cash and stock transaction valued at around $1.6 billion.